In a 66-year-old woman with a two-year history of untreated rheumatoid arthritis who now has anemia (hemoglobin 10 g/dL) with low mean corpuscular volume (MCV) and low mean corpuscular hemoglobin (MCH), what is the most appropriate therapeutic approach?

Initiate treatment for rheumatoid arthritis and re-evaluate the anemia

The most appropriate therapeutic approach is C) Initiation of treatment for rheumatoid arthritis and re-evaluation. In this 66-year-old woman with untreated RA presenting with microcytic anemia (low MCV and MCH), the priority must be addressing the underlying inflammatory disease while simultaneously investigating the specific cause of her anemia.

Rationale for Treating the Underlying RA First

The anemia in RA patients is multifactorial and commonly includes both anemia of chronic disease (ACD) and iron deficiency anemia (IDA). Critically, treating the inflammatory disease itself has been demonstrated to improve hemoglobin levels 1. Studies show that intensification of RA therapy, including DMARDs and biologics like TNF-α inhibitors, results in average hemoglobin increases of 1.3 g/dL 1. This patient has been untreated for two years, allowing chronic inflammation to persist unchecked.

Why Not Iron Alone (Option A)?

While the microcytic pattern suggests possible iron deficiency, in RA patients with anemia, 47% have true iron deficiency, but 53% have other causes including ACD 2. Simply administering iron without addressing the underlying inflammation may be ineffective because:

• Inflammatory cytokines in active RA impair iron absorption and utilization 3
• ACD causes functional iron deficiency where iron is sequestered and unavailable for erythropoiesis
• Iron supplementation alone fails to address the root cause when inflammation drives the anemia

The correct approach requires determining whether this is IDA, ACD, or both. A serum ferritin level is essential here - in inflammatory conditions like RA, ferritin can be falsely elevated, and ferritin <100 mg/dL in the setting of inflammation suggests concurrent iron deficiency 4. If ferritin is low (<45 mg/dL), iron supplementation should be added to RA treatment. If ferritin is 45-100 mg/dL, check transferrin saturation to confirm iron deficiency 4.

The Algorithmic Approach

1. Immediately initiate DMARD therapy for the untreated RA (this is overdue given her two-year disease duration)
2. Simultaneously obtain: serum ferritin, transferrin saturation, and inflammatory markers (CRP, ESR)
3. If ferritin <45 mg/dL or transferrin saturation <20%: Add iron supplementation (oral initially, IV if severe or malabsorption suspected) 4
4. If ferritin 45-100 mg/dL with elevated CRP/ESR: This suggests ACD with possible concurrent IDA - treat RA aggressively and consider iron supplementation
5. Re-evaluate hemoglobin in 8-12 weeks after RA treatment initiation

Why Not B12/Folate (Option B)?

The low MCV and MCH indicate microcytic anemia, not macrocytic anemia. B12 and folate deficiency cause macrocytic anemia (elevated MCV). This option is inappropriate for the laboratory findings presented.

Why Not Bone Marrow Biopsy (Option D)?

Bone marrow biopsy is invasive, expensive, and unnecessary at this stage 5. A simple algorithm using MCV, serum ferritin, and iron saturation correctly classifies 94% of iron deficiency cases and 85% of ACD cases in RA patients, avoiding the need for marrow sampling 5. Reserve bone marrow biopsy for cases where:

• Simple laboratory measures are inconclusive
• Anemia fails to respond to appropriate treatment
• Concern exists for myelodysplasia or other hematologic malignancy

Critical Pitfalls to Avoid

Do not assume all anemia in RA is simply ACD - this is a dangerous oversimplification. In one cohort, investigations of IDA in RA patients revealed gastrointestinal bleeding in 25 patients, with established malignancy in 10 patients and premalignancy in another 10 (representing 10% of all anemic RA patients) 2.

Therefore, while initiating RA treatment, also evaluate for blood loss: Check stool for occult blood, assess for NSAID use (common in RA patients and causes GI bleeding), and in this 66-year-old woman, ensure age-appropriate colon cancer screening is current.

Expected Outcomes

With appropriate RA treatment, expect hemoglobin improvement within 2-3 months. High disease activity, elevated inflammatory markers, and longer disease duration are all risk factors for persistent anemia 6, 7. If anemia persists despite controlled RA disease activity, then more aggressive investigation for other causes becomes warranted, including possible endoscopic evaluation for GI blood loss 4.

The two-year delay in treating her RA has likely contributed significantly to her anemia through chronic inflammation. Addressing the untreated RA is not just appropriate - it is urgent and overdue 8.